Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.